Risankizumab & Trosunilimab, Risankizumab & ABBV-701Study of Advanced Therapies for the Treatment of Adult Participants With Moderately to Severely Active Crohn's Disease or Ulcerative Colitis

Sponsor:

AbbVie

Code:

NCT07697456

Conditions

Crohn's Disease

Ulcerative Colitis

Eligibility Criteria

Sex: All

Age: 18 - 70+

Healthy Volunteers: Not accepted

Interventions

Risankizumab

Trosunilimab

ABBV-701

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information

Trial information was received from ClinicalTrials.gov and was last updated on 2026-09-02. This information was provided to ClinicalTrials.gov by AbbVie on 2026-08-31.